Urinary nitrite/nitrate concentrations and total antioxidant capacity in patients with chronic hepatitis C in therapy with interferon and ribavirin

被引:5
|
作者
Stanzial, AM
Benoni, G [1 ]
Cuzzolin, L
Gabrielli, GB
Pasino, M
Perfetti, P
Corrocher, R
机构
[1] Univ Verona, Dept Med & Publ Hlth, Pharmacol Sect, Policlin GB Rossi, I-37134 Verona, Italy
[2] Univ Verona, Dept Clin & Expt Med, I-37134 Verona, Italy
关键词
nitric oxide; hepatitis C; antioxidant capacity; therapy;
D O I
10.1179/joc.2003.15.6.584
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study we tried to elucidate the role of nitric oxide (NO) in chronic hepatitis C in relation to antioxidant status, since the mechanisms by which hepatitis C virus (HCV) causes cell damage and the factors underlying its resistance to therapy are not well understood. Before and after one and six months of therapy with alpha-interferon and ribavirin, we measured nitrite/nitrate urinary levels, total antioxidant capacity and selenium serum concentrations in 14 patients with chronic hepatitis C and in 9 healthy subjects. Before therapy, mean urinary nitrite/nitrate levels of patients were not different from those of healthy subjects, but after a 6-month treatment with alpha-interferon and ribavirin, these NO metabolites were higher in virologically negative patients (responders). Moreover, while no changes in selenium were observed in all patients, total antioxidant capacity was significantly higher in non-responders and well correlated with hyperuricemia (due to cell damage) observed in these subjects. Instead, uric acid decreased as free molecule in serum in responders, while we found the excretion of high NO levels as nitrite/nitrate. Our data allow us to hypothesize a role for NO as predictive of the success of therapy, since nitrite/nitrate increase in the urine of some patients precedes disappearance of the virus observed at the end of therapy.
引用
收藏
页码:584 / 590
页数:7
相关论文
共 50 条
  • [31] Is Combination Therapy Interferon and Ribavirin in Patients with Chronic Hepatitis C Infection Toxic for Eyes?
    Mousa, Nasser
    Besheer, Tarek
    Gad, Yahia
    Elbendary, Amal
    Mokbel, Tharwat
    Abdel-Aziz, Azza
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (03) : 345 - 348
  • [32] Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin
    Hoofnagle, JH
    Ghany, MG
    Kleiner, DE
    Doo, E
    Heller, T
    Promrat, K
    Ong, J
    Khokhar, F
    Soza, A
    Herion, D
    Park, Y
    Everhart, JE
    Liang, TJ
    HEPATOLOGY, 2003, 38 (01) : 66 - 74
  • [33] INTERFERON-GAMMA, INTERFERON-ALPHA AND RIBAVIRIN IN COMBINED THERAPY OF CHRONIC HEPATITIS C PATIENTS
    Sologub, T.
    Esaulenko, E.
    Volchek, I.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S350 - S350
  • [34] The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan
    Hiramatsu, N
    Kasahara, A
    Nakanishi, F
    Toyama, T
    Tsujii, M
    Tsuji, S
    Kanto, T
    Takehara, T
    Kato, M
    Yoshihara, H
    Naito, M
    Katayama, K
    Hijioka, T
    Hagiwara, H
    Kubota, S
    Oshita, M
    Meren, H
    Masuzawa, M
    Haruna, Y
    Mita, E
    Suzuki, K
    Hayashi, N
    HEPATOLOGY RESEARCH, 2004, 29 (03) : 142 - 147
  • [35] Treatment with amantadine plus ribavirin plus interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy.
    Ferenci, P
    Stauber, R
    Hackl, F
    Schuetze, K
    Bauer, B
    Datz, C
    GASTROENTEROLOGY, 2000, 118 (04) : A1437 - A1437
  • [36] Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine
    Rudolf E Stauber
    Harald Hofer
    Franz Hackl
    Kurt Schüze
    Christian Datz
    Karin Hegenbarth
    Wolfgang Jessner
    Petra Steindl-Munda
    Peter Ferenci
    Wiener Klinische Wochenschrift, 2004, 116 : 530 - 535
  • [37] Comparison of combination therapy of pegylated interferon and ribavirin with conventional interferon and ribavirin in chronic hepatitis C in Korea
    Kang, Myoung Joo
    Jung, Eun Uk
    Park, Sang Won
    Choi, Paul
    Kim, Ji Hyun
    Park, Sung Jae
    Park, Eun Taek
    Lee, Youn Jae
    Lee, Sang Hyuk
    Seol, Sang Yong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A217 - A217
  • [38] Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C
    Asahina, Y
    Izumi, N
    Enomoto, N
    Uchihara, M
    Kurosaki, M
    Onuki, Y
    Nishimura, Y
    Ueda, K
    Tsuchiya, K
    Nakanishi, H
    Kitamura, T
    Miyake, S
    JOURNAL OF HEPATOLOGY, 2005, 43 (04) : 623 - 629
  • [39] Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine
    Stauber, RE
    Hofer, H
    Hackl, F
    Schütze, K
    Datz, C
    Hegenbarth, K
    Jessner, W
    Steindl-Munda, P
    Ferenci, P
    WIENER KLINISCHE WOCHENSCHRIFT, 2004, 116 (15-16) : 530 - 535
  • [40] Interferon plus ribavirin retreatment in patients with chronic hepatitis C
    Kullig, U
    Porst, H
    Herrmann, A
    Wiese, M
    Schmidt, U
    Sundermann, U
    HEPATOLOGY, 1998, 28 (04) : 207A - 207A